New oral drug balinatunfib tested for long-term control of Crohn's and colitis
NCT ID NCT07222189
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at the long-term safety and effectiveness of balinatunfib, an oral tablet, in adults with Crohn's disease or ulcerative colitis. Participants have already completed a one-year treatment in a previous study. The trial will last up to 107 weeks and includes both double-blind and open-label periods. The main goal is to track side effects and see how well the drug controls the disease over time.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
balinatunfib (also known as SAR441566), an oral tablet
What this could lead to
If successful, this could show that balinatunfib is a safe long-term treatment option for managing Crohn's disease or ulcerative colitis.
What could go wrong
This is a Phase 2 extension study, so it's still early. The drug may not prove effective or safe over the long term, and side effects could emerge.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CROHN'S DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Investigational Site Number : 1000001
Gorna Oryahovitsa, 5100, Bulgaria
-
Investigational Site Number : 1520010
Santiago, Reg Metropolitana de Santiago, 8331143, Chile